Pfizer and OPKO’s Once-Weekly NGENLATM (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency :: OPKO Health, Inc. (OPK)

Jennifer E. Engen

Pfizer and OPKO’s Once-Weekly NGENLATM (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency     NEW YORK and MIAMI, February 15, 2022 – Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) […]

How Concerning Is Pfizer and Opko’s Latest FDA Rejection?

Jennifer E. Engen

The U.S. Food and Drug Administration (FDA) recently refused to approve Pfizer‘s (NYSE:PFE) and Opko Health‘s (NASDAQ:OPK) growth hormone therapy, somatrogon. In this Motley Fool Live video, recorded on Jan. 26, Motley Fool contributors Keith Speights and Brian Orelli discuss how concerning this rejection is for the two companies. Keith […]

Pfizer and OPKO’s Growth Hormone Deficiency Drug Denied by FDA

Jennifer E. Engen

Erik McGregor/LightRocket via Getty Shares of Opko Health plunged more than 16% in premarket trading after the U.S. Food and Drug Administration rejected the once-weekly human growth hormone somatrogon the company co-developed alongside Pfizer for the treatment of growth hormone deficiency (GHD) in pediatric patients. The FDA issued a Complete Response Letter for the Biologics […]